Compare United States Brent Oil Fund LP (BNO) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
United States Brent Oil Fund LP vs Viatris Inc — how do they compare? United States Brent Oil Fund LP trades at $50.42, while Viatris Inc trades at $16.28 (market cap $18.69B). The key difference: Viatris Inc pays a 2.95% dividend while United States Brent Oil Fund LP pays none, and Viatris Inc is trading nearer its 52-week high, United States Brent Oil Fund LP nearer its low. Which is the better fit depends on your goals.
| BNO | VTRS | |
|---|---|---|
Sector | Commodities - Energy | Health |
52-Week High | $60.13 | $17.86 |
52-Week Low | $27.20 | $9.49 |
Market Cap | — | $18.69B |
Enterprise Value | — | $30.80B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNO shows bullish momentum with a 1.22% gain to $50.72, supported by strong technical indicators including bullish moving averages. The oil market faces supply constraints from Middle East tensions and OPEC demand forecast cuts, creating volatility. Recent news highlights ongoing Strait of Hormuz disruptions affecting global oil flows, with the International Energy Agency warning of depleting stockpiles.
The outlook remains volatile with supply risks supporting prices, but demand destruction and inventory builds pose headwinds. Key resistance at $52 and support at $50 will determine near-term direction. Oil market fundamentals suggest continued price pressure from geopolitical factors, though weakening demand forecasts could limit upside potential.
Viatris (VTRS) trades at $16.105, down 1.07% on the day, with a bearish technical signal and mixed fundamentals. Recent Q2 2026 earnings beat estimates with EPS of $0.69 and revenue growth of 5%, but the company posted a net loss of $3.51B in 2025. Positive developments include FDA approval for Gwyn Lo and a raised 2026 outlook, though debt remains elevated at $14.04B long-term.
Outlook is cautious; while operational cash flow is strong at $2.32B and dividends provide income, persistent net losses and high P/E of 236.2 signal overvaluation risks. Analyst consensus leans Hold (61.54%), with upside potential if turnaround gains traction, but investors face headwinds from generic drug pricing pressures and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About United States Brent Oil Fund LP
BNO is a commodity ETF that tracks the daily price of Brent crude oil futures. It provides exposure to the international oil benchmark, which often trades at a premium to the U.S. WTI benchmark, and is primarily used for short-term trading due to roll costs.
Read more on BNO →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
